メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
Keio University ホーム
ヘルプ＆FAQ
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
正木 克宜
内科学(呼吸器)
ウェブサイト
https://k-ris.keio.ac.jp/html/100002716_ja.html
h-index
2339
被引用数
21
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2006
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(117)
類似のプロファイル
(6)
フィンガープリント
Katsunori Masakiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
66%
Cohort Study
65%
Disease
55%
Coronavirinae
54%
Chronic Obstructive Lung Disease
38%
Symptom
29%
Diseases
24%
SARS Coronavirus
22%
Infection
21%
Dyspnea
12%
Omalizumab
11%
Respiratory Tract Inflammation
11%
Mepolizumab
11%
Biological Marker
10%
Prospective Cohort Study
9%
Taste Disorder
8%
Ferritin
8%
Disease Course
7%
Lactate Dehydrogenase
6%
Allergic Airway Inflammation
6%
C Reactive Protein
6%
Retrospective Study
6%
Adverse Event
6%
Randomized Controlled Trial
6%
Hyperuricemia
6%
Obstructive Jaundice
5%
Transcription Factors
5%
Lipocortin 1
5%
Atypical Mycobacteriosis
5%
Interferon Antibody
5%
Corticosteroids Resistance
5%
Thymic Stromal Lymphopoietin
5%
Bronchiectasis
5%
Loeffler Pneumonia
5%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
5%
Atherosclerosis
5%
Autoantibodies
5%
Baricitinib
5%
Epinephrine
5%
Mucin 1
5%
RNA-Sequencing
5%
Bacteremia
5%
Vilanterol
5%
Fluticasone Furoate Plus Umeclidinium Plus Vilanterol
5%
Fluticasone Furoate
5%
Beta 2 Adrenergic Receptor Stimulating Agent
5%
Umeclidinium
5%
Icosapentaenoic Acid
5%
Lung Cancer
5%
Beta2 Agonist
5%
Medicine and Dentistry
COVID-19
100%
Cohort Analysis
34%
Coronavirinae
25%
Retrospective Cohort Study
24%
Diseases
23%
Disease
17%
Artificial Respiration
14%
Odds Ratio
14%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Dupilumab
11%
Omalizumab
11%
Postcovid Syndrome
10%
Infection
10%
Bacterial Infection
8%
Dyspnea
8%
Asthma
8%
Chronic Kidney Disease
7%
Disease Severity
7%
Chronic Obstructive Pulmonary Disease
7%
Quality of Life
7%
Lymphocyte
6%
Body Mass Index
6%
Ferritin
6%
Symptom
6%
Cardiovascular System
6%
Biological Marker
6%
Retrospective Study
6%
Adverse Event
6%
Disease Course
5%
Thymoma
5%
Randomized Controlled Trial
5%
Radiation Therapy
5%
Influenza B Virus
5%
Chest Radiograph
5%
Virulence Factor
5%
Quantitative Reverse Transcription Polymerase Chain Reaction
5%
Human Immunodeficiency Virus
5%
Needle Acupuncture
5%
Acupuncture Treatment
5%
Blood Cell
5%
Carbon Monoxide
5%
Lipocortin 1
5%
Lung Cancer
5%
Blood Pressure
5%
Respiratory Tract Inflammation
5%
T Cell
5%
Immune Deficiency
5%
Mepolizumab
5%
Benralizumab
5%
Self Injection
5%
Keyphrases
COVID-19
58%
Japan
40%
Odds Ratio
25%
Long COVID
23%
Chronic Obstructive Pulmonary Disease
18%
COVID-19 Outcomes
14%
Invasive Mechanical Ventilation
13%
Confidence Interval
13%
Asthma
13%
Japanese Patients
12%
Patients with COVID-19
12%
Long Coronavirus Disease
12%
COVID-19 Severity
12%
Smoking Exposure
11%
National Cohort Study
11%
Benralizumab
11%
Japanese Population
8%
Dyspnea
8%
Multicenter Cohort Study
8%
Patient Characteristics
8%
Risk Factors
7%
Pack-years
6%
Retrospective Cohort Study
6%
Hospitalized Patients
6%
Cysteinyl Leukotrienes
6%
Disease Severity
6%
Mechanical Ventilation
6%
Baricitinib
6%
Severe Disease
5%
Severe Asthma with Fungal Sensitization
5%
Fungal Sensitization
5%
SARS-CoV-2 Infection
5%
Fulminant Pneumonia
5%
High Virulence
5%
Viral Burden
5%
Severe Chronic Periodontitis
5%
Fifth Wave
5%
COVID-19 Sequelae
5%
Infection Waves
5%
Acupuncture Therapy
5%
Acupuncture Needle
5%
Adrenaline Auto-injector
5%
Metalloregulation
5%
Impaired Renal Function
5%
Prognostic Understanding
5%
Pre-existing Hypertension
5%
Barrier Factors
5%
Corticosteroid Resistance
5%
ABO Blood Group
5%
Japanese Nation
5%
